Dr. William Williams reports

BRIACELL PHASE 3 BRIA-IMT STUDY ENROLLMENT SURPASSES 230 PATIENTS

Briacell Therapeutics Corp.'s pivotal phase 3 Bria-ABC study has screened over 315 and enrolled over 230 patients. Briacell anticipates reporting top-line data in 2026.

Highlights:

• Over 315 patients screened and over 230 patients enrolled in Briacell's pivotal phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer;
• Enrolment momentum continues with strong clinical site and patient interest;
• Interim top-line data expected in 2026;
• Positive interim overall survival results could support potential approval of Bria-IMT in metastatic breast cancer;
• Briacell's Bria-IMT combination regimen continues under FDA (U.S. Food and Drug Administration) fast-track designation.

Briacell has received increased interest from leading cancer centres and continued enrolment momentum following the independent inclusion of its phase 3 clinical trial in Nature Medicine's article, "Eleven clinical trials that will shape medicine in 2026." The phase 3 Bria-ABC study is evaluating Briacell's lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician's choice of treatment in advanced breast cancer.

The interim analysis will be conducted after 144 patient events, defined as deaths, have occurred. Overall survival (OS) is the primary end point, and positive results could support full approval of Bria-IMT in patients with metastatic breast cancer. The Bria-IMT combination regimen has received FDA fast-track designation.

"Sustained and new interest from world-class institutions and their patients continues to drive remarkable patient engagement," stated Dr. William V. Williams, Briacell's president and chief executive officer. "We remain on track to report the interim analysis in 2026 while continuing to enroll patients and advance preparations for potential commercialization, with the goal of bringing our novel immunotherapy regimen to patients with metastatic breast cancer as efficiently as possible."

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.